» Authors » Kelly Westbrook

Kelly Westbrook

Explore the profile of Kelly Westbrook including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 199
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Hosseinian Z, Lehan A, Powers J, Melendez A, Fisher H, Shelby R, et al.
Contemp Clin Trials . 2024 Dec; 149:107780. PMID: 39706331
Background: Aromatase inhibitors (AIs) are a cornerstone of adjuvant systemic therapy for postmenopausal patients with hormone-receptor positive (HR+) breast cancer. Although AIs decrease cancer recurrence rates and improve survival rates,...
2.
Reese J, Lepore S, Sorice K, Zimmaro L, Hasler J, Handorf E, et al.
Cancer . 2024 Dec; 131(1):e35685. PMID: 39645589
Background: Sexual concerns are common and problematic for breast cancer survivors. Partner and relationship factors often play a key role in determining survivors' sexual adjustment, making it likely that couple-based...
3.
White O, Dent S, Westbrook K, Lee H, Yang C, Moore H
Breast Cancer Res Treat . 2024 May; 207(1):179-185. PMID: 38771399
Purpose: This study aimed to assess safety and efficacy of a modified KEYNOTE 522 protocol, which incorporated pembrolizumab every 6 weeks, allowing for concomitant dose-dense (14 day) doxorubicin and cyclophosphamide...
4.
Thomas A, OConnell N, Douglas E, Hatcher S, Park C, Dent S, et al.
Am Heart J . 2023 Oct; 267:33-43. PMID: 37890547
Survival with operable breast cancer has improved markedly in recent decades, however, treatment-related cardiovascular toxicities threaten to offset these gains. Ovarian function suppression paired with aromatase inhibition, for premenopausal women...
5.
Burnette S, Poehlein E, Lee H, Force J, Westbrook K, Moore H
Breast Cancer Res Treat . 2022 Nov; 197(2):369-376. PMID: 36409396
Purpose: SOLAR-1 investigated alpelisib-fulvestrant (ALP + FLV) in patients with HR + /HER2-, PIK3CA-mutated advanced breast cancer and demonstrated a clinically significant increase in all-grade and grade (G) 3-4 hyperglycemia...
6.
Griffiths E, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, et al.
J Natl Compr Canc Netw . 2022 May; 20(5):436-442. PMID: 35545171
The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia...
7.
Smith K, Verma N, Blackford A, Lehman J, Westbrook K, Lim D, et al.
NPJ Breast Cancer . 2022 Apr; 8(1):53. PMID: 35449210
Many patients discontinue endocrine therapy for breast cancer due to intolerance. Identification of patients at risk for discontinuation is challenging. The minimal important difference (MID) is the smallest change in...
8.
Langer S, Romano J, Keefe F, Baucom D, Strauman T, Syrjala K, et al.
Front Psychol . 2022 Feb; 12:769407. PMID: 35222142
Cancer and its treatment pose challenges that affect not only patients but also their significant others, including intimate partners. Accumulating evidence suggests that couples' ability to communicate effectively plays a...
9.
Carson J, Carson K, Olsen M, Sanders L, Westbrook K, Keefe F, et al.
J Pain Symptom Manage . 2020 Oct; 61(6):1227-1233. PMID: 33065208
Context: Women with metastatic breast cancer (MBC) experience a significant symptom burden, including cancer pain. Yoga is a mind-body discipline that has shown promise for alleviating cancer pain, but few...
10.
Reese J, Zimmaro L, Lepore S, Sorice K, Handorf E, Daly M, et al.
Trials . 2020 Feb; 21(1):173. PMID: 32051002
Background: Sexual concerns are distressing for breast cancer survivors and interfere with their intimate relationships. This study evaluates the efficacy of a four-session couple-based intervention delivered via telephone, called Intimacy...